These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 9009470

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine.
    Silberstein SD, Kori SH.
    CNS Drugs; 2013 May; 27(5):385-94. PubMed ID: 23620146
    [Abstract] [Full Text] [Related]

  • 23. Carotid vascular effects of ergotamine and dihydroergotamine in the pig: no exclusive mediation via 5-HT1-like receptors.
    den Boer MO, Heiligers JP, Saxena PR.
    Br J Pharmacol; 1991 Sep; 104(1):183-9. PubMed ID: 1664762
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy.
    Tas C, Joyce JC, Nguyen HX, Eangoor P, Knaack JS, Banga AK, Prausnitz MR.
    J Control Release; 2017 Dec 28; 268():159-165. PubMed ID: 29051065
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Dihydroergotamine: role in the treatment of migraine.
    Schürks M.
    Expert Opin Drug Metab Toxicol; 2009 Sep 28; 5(9):1141-8. PubMed ID: 19624283
    [Abstract] [Full Text] [Related]

  • 29. Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines.
    Lesage AS, Wouters R, Van Gompel P, Heylen L, Vanhoenacker P, Haegeman G, Luyten WH, Leysen JE.
    Br J Pharmacol; 1998 Apr 28; 123(8):1655-65. PubMed ID: 9605573
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Dihydroergotamine: pharmacokinetics, pharmacodynamics, and mechanism of venoconstrictor action in beagle dogs.
    Müller-Schweinitzer E, Rosenthaler J.
    J Cardiovasc Pharmacol; 1987 Jun 28; 9(6):686-93. PubMed ID: 2442535
    [Abstract] [Full Text] [Related]

  • 33. Effects of ergotamine and dihydroergotamine on 5-hydroxytryptamine-2A receptors in the isolated rat aorta.
    Kalkman HO, Schneider F.
    Pharmacology; 1996 Dec 28; 53(6):351-5. PubMed ID: 9032799
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Ergotamine: its use in the treatment of migraine and its complications.
    Saxena VK, De Deyn PP.
    Acta Neurol (Napoli); 1992 Apr 28; 14(2):140-6. PubMed ID: 1329442
    [Abstract] [Full Text] [Related]

  • 36. Present and future of 5-HT receptor agonists as antimigraine drugs.
    Pauwels PJ, John GW.
    Clin Neuropharmacol; 1999 Apr 28; 22(3):123-36. PubMed ID: 10367177
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a Novel (Tempo) inhaler.
    Shrewsbury SB, Cook RO, Taylor G, Edwards C, Ramadan NM.
    Headache; 2008 Mar 28; 48(3):355-67. PubMed ID: 18179563
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.